Skip to content

Injection of product derived from patient own blood into the knee and assess for improvement in pain and disability in patient suffering from osteoarthritis of knee

Randomized trial to evaluate the efficacy of intra- articular injection of Growth factor concentrates with regards to improvement in pain and disability in patients suffering from osteoarthritis of knee

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/11/047634
Enrollment
75
Registered
2022-11-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M171- Unilateral primary osteoarthritisof knee

Interventions

Intervention1: Growth factor concentrate: Growth factor factor (2ml) concentrate which will be derived from patients own blood (4ml ) will be injected in the affected knee under USG guidance under ase

Sponsors

Hospital supply
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Confirmed cases of osteoarthritis knee (kellgren Lawrence classification grade 2-3) • NRS > 4 (Due to knee disease) not responding to conservative treatment

Exclusion criteria

Exclusion criteria: Exclusion criteria • Uncontrolled Systemic diseases- diabetes mellitus, immunodeficiency and collagen vascular disease , presence or history of malignancy , presence of auto immune disease or platelet disorders • BMI > 33 kg/m2 • History of systemic steroids during 2 weeks prior to injection • Any intra-articular injection in knee 3 months prior to enrolment in study • History of recent knee trauma or knee septic arthritis • Patients receiving anticoagulation therapy • Pregnant females • Presence of genu varum or valgum over 20 degrees. • Patients refusal

Design outcomes

Primary

MeasureTime frame
. To Assess the pain score with intra articular injection of dextrose 25% Vs GFC single dose Vs GFC two doses at pre procedure, Post procedure, 3weeks,2 month , 6 month and 12 month duration â?¢ To assess WOMAC score for disability To assess the patient satisfaction at 2 monthTimepoint: . To Assess the pain score with intra articular injection of dextrose 25% Vs GFC single dose Vs GFC two doses at pre procedure, Post procedure, 3weeks,2 month , 6 month and 12 month duration â?¢ To assess WOMAC score for disability To assess the patient satisfaction at 2 month

Secondary

MeasureTime frame
To assess WOMAC score for disability To assess the patient satisfactionTimepoint: 2 month

Countries

India

Contacts

Public ContactSweta salgoankar

Kem hospital

Swetavs@gmail.com9521088934

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026